Cardiol Therapeutics ($CRDL) Is Further Along Than Most Inflammation Cardiology Plays

Big Pharma is clearly leaning into inflammation in cardiovascular disease. Lilly’s $1.2B acquisition of Ventyx Biosciences, Novartis’ $1.4B acquisition of Tourmaline Bio, and Monte Rosa Therapeutics’ $300M raise make that obvious. 

Most companies in this theme are still early stage. Cardiol Therapeutics ($CRDL) is already executing at the late clinical stage. 

CardiolRx™, with U.S. FDA Orphan Drug Designation granted in 2024, is being evaluated in the pivotal Phase 3 MAVERIC trial for recurrent pericarditis. Enrollment already exceeds 50%, and full enrollment is targeted for Q2 2026. 

In the Phase 2 ARCHER trial in acute myocarditis, CardiolRx™ showed a statistically significant reduction in left ventricular (LV) mass over 12 weeks. LV mass is tied to cardiac remodeling and long-term heart failure risk, so this provides controlled clinical proof of concept that targeting inflammation may improve heart structure. 

The company is also advancing CRD-38, a subcutaneous formulation intended for heart failure and is completing IND-enabling studies. 

Management has stated the company is funded through MAVERIC’s full enrollment and data readout, with runway expected into Q3 2027. A U.S. patent allowance extends protection into 2040. 

Still clinical stage biotech. But within the cardiac inflammation theme, this is one of the few names with a pivotal trial and defined regulatory milestones over the next 6 to 12 months. 

Not financial advice.